That's putting it mildly Kool. This stock will get played with for the foreseeable future until material news changes the paradigm. Again, didn't see it coming, but everyone is playing the same waiting game except the market makers. They'll keep this out of the spotlight with it's very disinteresting price movement. Every morning the same 4500 shares sells. Then there is the bio's in general.......perhaps ALIM has some silver lining with its CC, but we've been thinking that for some time now too.
There is nothing sacred about the market. It is a collection of companies hardly worth their weight. Dare I say it one more time.......We're going higher but for right now and in this market we are stuck.......until we get some news. It could come on any of a variety of fronts, we'll all know when that is. Until then, we're stuck here and it makes me feel like I've been run over by the market bus.
Kool. Another thing to consider here is the duration. pSivida's product will no doubt have a six month primary end point at a minimum in a trial vs. 12 weeks (FLEX), with the potential for years of drug delivery. This is a huge advantage for pSivida ; hence the Durasert platform.
Terry, The North Run Capital website shows a decrease of 175K in pSivida stock, this total is now 1.9 Million m/l. They held on to all 3.5 Million of Alimera stock. I guess you can't read too much into it, they just took 8% off the table.
Have to agree with you here Hernando. I'm looking forward to seeing some advancement in Iluvien sales with the upcoming Alimera CC in March.
Many of us thought this very thing about Alimera's Iluvien. This was because at the time there were no approved drugs for DME. Then, the anti VEG-F's and Ozurdex got approved long before Iluvien for the indication. So, many have been here for a very long time. And though we recognize the broad potential of the company, just as you do, we've watched timelines extend for years. We'll most likely all be here just the same in spite of the company missing them.
Vero, They've spent money like drunken sailors for the last year. They've had a sales force with retina doc's not wanting to buy the drug and wait months on end to get paid. Hopefully, by the next CC, there will be some sign of increased sales with the J code. If not, raising money in this environment will leave a mark.
Sad to say....besides great data on Medidur, we've got 6-8 months of volatility in a company that announces little news to boost its SP. So, the new Hedge funds that came it at $4 look just as clueless as we do. Don't they? Why on earth buy 4 million shares at $4 when you can watch pSivida stock drop to $3 or less.......three weeks later? Now I know the broad market stinks and bio's in particular are getting slammed. pSivida has always been undervalued but still not immune to a broad sell off. I wish I knew....in the meantime, I scratch my head as to what if anything is happening behind the scenes. Most Hedge funds aren't as dumb as we are, so why buy in when they did? Now that I've had time to reflect on the sequence of events, this wasn't Paul's finest moment with selling stock, raising capital below his sale price, then watching the SP free fall immediately thereafter. If I saw it coming, I would have sold all my position at the highs, only to buy it back at current levels. After all , 45% is a lot of capital.
I do not recall that.......but it's a rough patch we're all going through, to say the least........